Results 291 to 300 of about 460,858 (405)
Are two drugs better than one in advanced NSCLC? ABSTRACT Background Randomized studies have demonstrated superior overall survival (OS) of pembrolizumab (pembro), both alone and in combination with chemotherapy (chemo) over chemo alone in patients with programmed cell death ligand‐1 (PD‐L1) ≥ 50% advanced non–small cell lung cancer (NSCLC).
Junipearl Cheng +5 more
wiley +1 more source
Low-molecular-weight heparin alleviates L-arginine-induced acute pancreatitis by modulating lipid metabolism and inflammatory responses in a rat model. [PDF]
Zeng J +5 more
europepmc +1 more source
Clinical practice guideline: management of acute pancreatitis.
J. Greenberg +9 more
semanticscholar +1 more source
A machine learning model using predialysis data predicted sudden events during or after hemodialysis with high accuracy (auROC: 0.889). The key predictors included emergency hospitalization, recent surgery, high heart rate, low albumin levels, and high CRP.
Naotaka Kato +11 more
wiley +1 more source
Acute Pancreatitis Presenting as Inferior Wall Myocardial Ischaemia: A Case Report. [PDF]
Ferreira I +4 more
europepmc +1 more source
Acute Pancreatitis and Pancreatic Cancer Risk: A Nationwide Matched-Cohort Study in Denmark.
J. Kirkegård +3 more
semanticscholar +1 more source
Risk prediction of all-cause mortality in hospitalized patients with severe acute pancreatitis by serum urea nitrogen/albumin ratio. [PDF]
Qiu H +6 more
europepmc +1 more source
In this population‐based study the relapse rates were remarkably low in patients reaching day 79 with active treatment, challenging the widely accepted belief that ALL is difficult to cure in the elderly. Summary Population data have shown that the prognosis for elderly patients with acute lymphoblastic leukaemia (ALL) is poor, even in the modern era ...
P. Quist‐Paulsen +8 more
wiley +1 more source
Endovascular embolization of pancreatic arteriovenous malformation associated with acute pancreatitis. [PDF]
Yang J, Zhu Q, Zhang H.
europepmc +1 more source

